专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007059625A1 BACTERIAL ANTIGENS AND USES THEREOF 审中-公开
标题翻译：细菌抗原及其用途
公开(公告)号：WO2007059625A1
公开(公告)日：2007-05-31
申请号：PCT/CA2006/001927
申请日：2006-11-23
申请人： NATIONAL RESEARCH COUNCIL OF CANADA , COX, Andrew , NEELAMEGAN, Dhamodharan , SCHOENHOFEN, Ian , ST. MICHAEL, Frank , RICHARDS, James, C.
发明人： COX, Andrew , NEELAMEGAN, Dhamodharan , SCHOENHOFEN, Ian , ST. MICHAEL, Frank , RICHARDS, James, C.
IPC分类号： C12P19/04 , A61K38/14 , A61K39/02 , A61K39/095 , A61K39/102 , A61P31/04 , C12N9/24
CPC分类号： A61K39/095 , A61K39/02 , A61K39/0208 , A61K39/102 , A61K2039/6037 , C12P19/44
摘要： Novel enzymes, processes and antigenic structures useful in producing vaccines and compounds useful in combating gram-negative bacteria are described. Enzymes were isolated from the slime mould Dictyostelium discoideum and used to specifically degrade lipopolysaccharide (LPS). Enzymatic degradation permits residues of the LPS molecule, including immunogenic epitopes of the core oligosaccharide portion of the LPS, to remain unmodified during this enzymatic removal of fatty acids from the lipid A region of the LPS molecule.
摘要翻译：描述了可用于生产用于对抗革兰氏阴性细菌的疫苗和化合物的新型酶，过程和抗原结构。从粘液霉菌盘基网柄菌中分离出酶

2. 发明申请

WO0216440A8 HAEMOPHILUS INFLUENZAE LIPOPOLYSACCHARIDE INNER-CORE OLIGOSACCHARIDE EPITOPES AS VACCINES FOR THE PREVENTION OF HAEMOPHILUS INFLUENZAE INFECTIONS 审中-公开
标题翻译： HAEMOPHILUS INFLUENZAE LIPOPOLYSACCHARIDE内核寡糖抗原决定子作为疫苗用于预防肝炎流感病毒感染
公开(公告)号：WO0216440A8
公开(公告)日：2002-11-14
申请号：PCT/CA0101225
申请日：2001-08-27
申请人： AVENTIS PASTEUR , RICHARDS JAMES C , COX ANDREW , MOXON RICHARD , HOOD DEREK , SCHWEDA ELKE K H , MAANSSON MARTIN
发明人： RICHARDS JAMES C , COX ANDREW , MOXON RICHARD , HOOD DEREK , SCHWEDA ELKE K H , MAANSSON MARTIN
IPC分类号： C12N15/09 , A61K39/145 , A61K39/395 , A61P31/16 , C07K16/12 , C08B37/00 , C12P21/08 , A61K39/102
CPC分类号： C07K16/1242 , C08B37/00
摘要： The present invention relates to a lipopolysaccharide moiety comprising a conserved triheptosyl inner-core moiety of lipopolysaccharide substantially free of variable outer core oligosaccharide chain extension, and to vaccines obtaines therefrom which are cross-reactive for Haemophilus influenzae strains. The invention also relates to defined mutations in the biosynthetic machinery for lipopolysaccharide (LPS) expression in Haemophilus influenzae useful to obtain the abovementioned moiety. The invention also relates to using conjugates of the LPS from the mutant strains so obtained to elicit a heterologous immune response against a wide range of disease-causing H. influenzae strains. More specifically, the invention relates to vaccines for prevention of bacterial infections comprising core lipopolysaccharide of Haemophilus influenzae . A lipopolysaccharide moiety comprising a conserved triheptosylinner-core moiety of lipopolysaccharide substantially free of variable outer core oligosaccharide chain extensions.
摘要翻译：本发明涉及脂多糖部分，其包含基本上不含可变外核寡糖链延伸的脂多糖的保守的三巯基内核部分，以及从其中获得的流感嗜血杆菌菌株具有交叉反应性的疫苗。本发明还涉及用于获得上述部分的流感嗜血杆菌中脂多糖（LPS）表达的生物合成机理中的定义突变。本发明还涉及使用如此获得的突变菌株的LPS的缀合物，以引发针对各种致病流感嗜血杆菌菌株的异源免疫应答。更具体地，本发明涉及用于预防细菌感染的疫苗，其包含流感嗜血杆菌的核心脂多糖。脂多糖部分，其包含基本上不含可变外核寡糖链延伸的脂多糖的保守的三巯基乙烯酮核心部分。

3. 发明申请

WO2003070282A2 SYNTHESIS OF LIPOPOLYSACCHARIDE-PROTEIN CONJUGATE VACCINES VIA THE LIPID A REGION FOLLOWING REMOVAL OF THE GLYCOSIDIC PHOSPHATE RESIDUE 审中-公开
标题翻译：通过去除糖苷磷酸盐残留物的脂肪酸区域合成脂多糖 - 蛋白质结合疫苗
公开(公告)号：WO2003070282A2
公开(公告)日：2003-08-28
申请号：PCT/CA2003/000254
申请日：2003-02-24
申请人： NATIONAL RESEARCH COUNCIL OF CANADA , JENNINGS, Harold , MIESZALA, Malgorzata , KOGAN, Grigorij , ZOU, Wei , RICHARDS, James, C. , COX, Andrew , MOXON, Richard
发明人： JENNINGS, Harold , MIESZALA, Malgorzata , KOGAN, Grigorij , ZOU, Wei , RICHARDS, James, C. , COX, Andrew , MOXON, Richard
IPC分类号： A61K47/48
CPC分类号： A61K47/646
摘要： This invention relates to lipopolysaccharide-protein conjugate vaccines with appropriate presentation of conserved inner core oligosaccharide epitopes having improved immunogenic properties. These are based upon antigenic, detoxified bacterial lipopolysaccharides which optimally present an inner core oligosaccharide epitope following removal of at least a glycosidic phosphate of the lipid A region. These partially or completely dephosphorylated antigenic, detoxified bacterial lipopolysaccharides are linkable to an immunologically acceptable carrier and can be used in polyvalent or multivalent vaccines.
摘要翻译：本发明涉及具有改善的免疫原性的保守的内核寡糖表位的适当呈递的脂多糖 - 蛋白质结合疫苗。这些是基于抗原性，解毒的细菌脂多糖，其在去除脂质A区域的至少糖苷磷酸酯之后最佳地呈现内核寡糖表位。这些部分或完全去磷酸化的抗原性，解毒的细菌脂多糖可与免疫学上可接受的载体连接，可用于多价或多价疫苗。

4. 发明申请

WO2002016440A3 HAEMOPHILUS INFLUENZAE LIPOPOLYSACCHARIDE INNER-CORE OLIGOSACCHARIDE EPITOPES AS VACCINES FOR THE PREVENTION OF HAEMOPHILUS INFLUENZAE INFECTIONS 审中-公开
公开(公告)号：WO2002016440A3
公开(公告)日：2002-02-28
申请号：PCT/CA2001/001225
申请日：2001-08-27
申请人： AVENTIS PASTEUR LIMITED , RICHARDS, James, C. , COX, Andrew , MOXON, Richard , HOOD, Derek , SCHWEDA, Elke, K. H. , Månsson Martin
发明人： RICHARDS, James, C. , COX, Andrew , MOXON, Richard , HOOD, Derek , SCHWEDA, Elke, K. H. , Månsson Martin
IPC分类号： C08B37/00
摘要： The present invention relates to a lipopolysaccharide moiety comprising a conserved triheptosyl inner-core moiety of lipopolysaccharide substantially free of variable outer core oligosaccharide chain extension, and to vaccines obtaines therefrom which are cross-reactive for Haemophilus influenzae strains. The invention also relates to defined mutations in the biosynthetic machinery for lipopolysaccharide (LPS) expression in Haemophilus influenzae useful to obtain the abovementioned moiety. The invention also relates to using conjugates of the LPS from the mutant strains so obtained to elicit a heterologous immune response against a wide range of disease-causing H. influenzae strains. More specifically, the invention relates to vaccines for prevention of bacterial infections comprising core lipopolysaccharide of Haemophilus influenzae . A lipopolysaccharide moiety comprising a conserved triheptosylinner-core moiety of lipopolysaccharide substantially free of variable outer core oligosaccharide chain extensions.

5. 发明申请

WO2012118592A1 DEVICE AND METHOD FOR ADMINISTERING ORAL DISINFECTING SOLUTIONS AND OTHER MEDICAMENTS 审中-公开
标题翻译：用于管理口腔消毒溶液和其他药物的装置和方法
公开(公告)号：WO2012118592A1
公开(公告)日：2012-09-07
申请号：PCT/US2012/023462
申请日：2012-02-01
申请人： ASSURE PET HEALTH, INC. , RICHARDS, James, C.
发明人： RICHARDS, James, C.
IPC分类号： A01K7/06
CPC分类号： A61B17/0401 , A01K7/02 , A01K7/06 , A61B17/0482 , A61B17/0485 , A61B17/0487 , A61B17/06061 , A61B17/842 , A61B2017/0414 , A61B2017/047 , A61B2017/0496 , A61F2/442 , A61F2002/30677 , A61F2002/4435 , A61F2210/0004 , A61F2230/0008 , A61F2230/0023 , A61F2230/0069 , A61F2310/00365
摘要： Embodiments of the present invention feature devices and methods for administering medicaments to subjects and, in particular, molecular iodine to animals in drinking water for the treatment of oral bad breath and disease. An exemplary device comprises a source of medicament in a fluid, measuring means, an administration switch and a water reservoir means. The measuring means is in fluid communication with said source of medicament for measuring an aliquot of medicament corresponding to a dose for the treatment of a disease. The measuring means is also in communication with a water reservoir means and releases the aliquot into the water reservoir means upon signal activation. The administration switch means is in signal communication with the measuring means and upon activation by a subject produces an activation signal received by the measuring means. The water reservoir means is for receiving the aliquot and forming an aqueous solution of medicament.
摘要翻译：本发明的实施方案的特征在于用于向受试者施用药物的装置和方法，特别是用于饮用水中的动物的分子碘用于治疗口腔口臭和疾病。示例性装置包括流体中的药物源，测量装置，给药开关和储水装置。测量装置与所述药物源流体连通，用于测量对应于治疗疾病的剂量的药物等分试样。测量装置还与储水装置连通并且在信号激活时将等分试样释放到储水装置中。管理开关装置与测量装置进行信号通信，并且在被对象激活时产生由测量装置接收的激活信号。储水装置用于接收等份并形成药物的水溶液。

6. 发明申请

WO2008005194A2 METHOD FOR THE ERADICATION OF PATHOGENS INCLUDING S. AUREUS AND ANTIBIOTIC RESISTANT MICROBES FROM THE UPPER RESPIRATORY TRACT OF MAMMALS AND FOR INHIBITING THE ACTIVATION OF IMMUNE CELLS 审中-公开
标题翻译：用于消除病原体的方法，其包括来自上调呼吸道感染的金丝桃和抗生素抗性微生物并抑制免疫细胞的激活
公开(公告)号：WO2008005194A2
公开(公告)日：2008-01-10
申请号：PCT/US2007/014456
申请日：2007-06-21
申请人： SYMBOLLON PHARMACEUTICAL, INC. , KESSLER, Jack, H. , RICHARDS, James, C.
发明人： KESSLER, Jack, H. , RICHARDS, James, C.
CPC分类号： A61K31/724 , A61K33/18 , A61K2300/00
摘要： A method for killing or substantially eradicating a pathogen in the upper respiratory tract of a mammal is disclosed. The method comprises generating molecular iodine (12) in situ using an oxidant-reductant reaction with a minimum concentration of at least about 25 ppm of I2 and I2 comprises at least 40% of the total iodine atoms. A method for inhibiting superantigens using molecular iodine is also disclosed.
摘要翻译：公开了杀死或基本上消除哺乳动物上呼吸道中的病原体的方法。该方法包括使用至少约25ppm的I 2的最小浓度的氧化剂 - 还原剂反应原位产生分子碘（12），并且I 2占总碘原子的至少40％。还公开了使用分子碘抑制超抗原的方法。

7. 发明申请

WO0216440A9 HAEMOPHILUS INFLUENZAE LIPOPOLYSACCHARIDE INNER-CORE OLIGOSACCHARIDE EPITOPES AS VACCINES FOR THE PREVENTION OF HAEMOPHILUS INFLUENZAE INFECTIONS 审中-公开
标题翻译： HAEMOPHILUS INFLUENZAE LIPOPOLYSACCHARIDE内核寡糖抗原决定子作为预防肝炎流感病毒感染的疫苗
公开(公告)号：WO0216440A9
公开(公告)日：2004-05-13
申请号：PCT/CA0101225
申请日：2001-08-27
申请人： AVENTIS PASTEUR , RICHARDS JAMES C , COX ANDREW , MOXON RICHARD , HOOD DEREK , SCHWEDA ELKE K H , MAANSSON MARTIN
发明人： RICHARDS JAMES C , COX ANDREW , MOXON RICHARD , HOOD DEREK , SCHWEDA ELKE K H , MAANSSON MARTIN
IPC分类号： C12N15/09 , A61K39/145 , A61K39/395 , A61P31/16 , C07K16/12 , C08B37/00 , C12P21/08 , A61K39/102
CPC分类号： C07K16/1242 , C08B37/00
摘要： The present invention relates to a lipopolysaccharide moiety comprising a conserved triheptosyl inner-core moiety of lipopolysaccharide substantially free of variable outer core oligosaccharide chain extension, and to vaccines obtaines therefrom which are cross-reactive for Haemophilus influenzae strains. The invention also relates to defined mutations in the biosynthetic machinery for lipopolysaccharide (LPS) expression in Haemophilus influenzae useful to obtain the abovementioned moiety. The invention also relates to using conjugates of the LPS from the mutant strains so obtained to elicit a heterologous immune response against a wide range of disease-causing H. influenzae strains. More specifically, the invention relates to vaccines for prevention of bacterial infections comprising core lipopolysaccharide of Haemophilus influenzae. A lipopolysaccharide moiety comprising a conserved triheptosylinner-core moiety of lipopolysaccharide substantially free of variable outer core oligosaccharide chain extensions.
摘要翻译：本发明涉及脂多糖部分，其包含基本上不含可变外核寡糖链延伸的脂多糖的保守的三巯基内核部分，以及从其中获得的流感嗜血杆菌菌株具有交叉反应性的疫苗。本发明还涉及用于获得上述部分的流感嗜血杆菌中脂多糖（LPS）表达的生物合成机理中的定义突变。本发明还涉及使用如此获得的突变菌株的LPS的缀合物，以引发针对各种致病流感嗜血杆菌菌株的异源免疫应答。更具体地，本发明涉及用于预防细菌感染的疫苗，其包含流感嗜血杆菌的核心脂多糖。脂多糖部分，其包含基本上不含可变外核寡糖链延伸的脂多糖的保守的三巯基乙烯酮核心部分。

8. 发明申请

WO2010025542A1 LPS BASED VACCINES 审中-公开
标题翻译：基于LPS的疫苗
公开(公告)号：WO2010025542A1
公开(公告)日：2010-03-11
申请号：PCT/CA2009/001201
申请日：2009-09-08
申请人： NATIONAL RESEARCH COUNCIL OF CANADA , COX, Andrew, D. , ST. MICHAEL, Frank , RICHARDS, James, C. , MOXON, E. Richard
发明人： COX, Andrew, D. , ST. MICHAEL, Frank , RICHARDS, James, C. , MOXON, E. Richard
IPC分类号： C08B37/00 , A61K39/095 , A61K39/102 , A61K39/385 , A61P31/04 , A61P37/04
CPC分类号： A61K39/095 , A61K39/102 , A61K39/1045 , A61K2039/55566 , A61K2039/6037 , C08B37/0063
摘要： The removal of the glycosidic phosphate from the reducing end of the derived LPS molecule creates an aldehydo functionality which causes the formation of an immunologically dominant neo-epitope. Conjugation to the reducing end of a carbohydrate molecule following removal of the glycosidic phosphate traps the reducing glucosamine residue in an open-chain form which surprisingly was found to dominate the immune response. We therefore modified our conjugation strategy to avoid this open-chain form, by utilising the amino functionality created by the isolated amidase activity from Dictyostelium discoideum, concomitant with a unique blocking and un-blocking strategy to protect the immunologically important phosphoethanolamine inner core residue. These antigenic structures are useful in producing vaccines and compounds helpful in combating Gram-negative bacteria. Also described are specific structures of the carbohydrate molecules derived from a variety of Gram-negative bacteria, which when presented appropriately as a glycoconjugate will facilitate a functional immune response to the target core oligosaccharide region.
摘要翻译：从衍生的LPS分子的还原端去除糖苷磷酸形成醛官能团，其导致形成免疫优势的新表位。在除去糖苷磷酸盐后，与碳水化合物分子的还原末端的缀合物以开放链形式释放还原葡糖胺残基，令人惊讶地发现其主导免疫应答。因此，我们修改了我们的共轭策略，以避免这种开链形式，通过利用由盘基网柄菌分离的分离的酰胺酶活性产生的氨基功能，伴随着独特的阻断和非阻断策略来保护免疫重要的磷酸乙醇胺内核残基。这些抗原结构可用于生产有助于抵抗革兰氏阴性菌的疫苗和化合物。还描述了衍生自各种革兰氏阴性细菌的碳水化合物分子的特异性结构，当作为糖缀合物适当地呈现时，将促进对靶核心寡糖区域的功能性免疫应答。

9. 发明申请

WO2010025541A1 IDENTIFICATION OF A CONSERVED INNER CORE OLIGOSACCHARIDE REGION OF MORAXELLA CATARRHALIS LIPOPOLYSACCHARIDE AS A VACCINE ANTIGEN 审中-公开
标题翻译：鉴定作为疫苗抗原的莫拉西拉天冬酰胺胆碱酯酶的内核寡核苷酸区域的鉴定
公开(公告)号：WO2010025541A1
公开(公告)日：2010-03-11
申请号：PCT/CA2009/001193
申请日：2009-09-04
申请人： NATIONAL RESEARCH COUNCIL OF CANADA , COX , Andrew, D. , RICHARDS , James, C .
发明人： COX , Andrew, D. , RICHARDS , James, C .
IPC分类号： C08B37/00 , A61K39/00 , A61K39/385 , A61P31/04 , A61P37/04 , C07K16/12 , A61K39/104 , C12P21/08 , A61K31/739
CPC分类号： C07K16/1214 , A61K39/1045 , A61K2039/505 , A61K2039/6087
摘要： There are disclosed herein antigenic structures useful in producing vaccines against and compounds helpful in combating diseases caused by the bacterium Moraxella catarrhalis. Disclosed are specific structures of the carbohydrate molecules derived from genetically engineered strains of Moraxella catarrhalis, which when presented appropriately to the immune system will facilitate a functional immune response to the target core oligosaccharide region.
摘要翻译：本文公开了可用于生产疫苗的抗原结构和有助于对抗由细菌莫拉氏杆菌引起的疾病的化合物。公开了衍生自卡介氏莫拉氏杆菌的遗传工程菌株的碳水化合物分子的特异性结构，当其适当地递送到免疫系统时将促进对靶核心寡糖区域的功能性免疫应答。

10. 发明申请

WO2005111196A1 CONSERVED INNER CORE LIPOPOLYSACCHARIDE EPITOPES AS MULTI-SPECIES VACCINE CANDIDATES 审中-公开
标题翻译：作为多品种疫苗候选物保留内核脂多糖
公开(公告)号：WO2005111196A1
公开(公告)日：2005-11-24
申请号：PCT/CA2005/000745
申请日：2005-05-16
申请人： NATIONAL RESEARCH COUNCIL CANADA , COX, Andrew , RICHARDS, James, C.
发明人： COX, Andrew , RICHARDS, James, C.
IPC分类号： C12N1/20
CPC分类号： C12N1/36 , A61K31/739 , A61K39/0208 , A61K39/05 , A61K39/102 , A61K47/646 , A61K2039/505 , A61K2039/522 , A61K2039/552 , A61K2039/6081 , A61K2039/70 , C07H3/06 , C07H13/04 , C07K16/1242 , C08B37/0003 , C08B37/006 , C12P19/04 , C12P19/44 , C12R1/01
摘要： A conserved inner-core oligosaccharide epitope expressed on the lipopolysaccharide (LPS) of a range of disease causing pathogenic bacterial isolates, including Actinobacillus pleuropneumoniae (Ap), Mannheimia haemolytica (Mh) and Pasteurella multocida (Pm), is disclosed. Construction of a mutant bacterial strain exclusively expressing the conserved inner core OS epitope as a terminally exposed structure has allowed the identification, production and isolation of an inner core LPS which is common to all three organisms. Further provided are associated vaccines, antibodies raised against the conserved LPS inner core and glycoconjugates comprising the LPS inner core linked to an immunogenic carrier.
摘要翻译：公开了在致病细菌分离物的一系列疾病的脂多糖（LPS）上表达的保守的内核寡糖表位，包括放线杆菌胸膜肺炎放线芽孢杆菌（Ap），溶血性马氏解毒血症（Mh）和多杀巴斯德氏菌（Pm））。构建仅表达保守的内核OS表位作为末端暴露结构的突变细菌菌株允许鉴定，产生和分离所有三种生物共同的内核LPS。还提供了相关疫苗，针对保守的LPS内核产生的抗体和包含与免疫原性载体连接的LPS内核的糖缀合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式